RU2685502C2 - Терапевтические агенты для применения в профилактике и/или лечении гиперкинетических двигательных расстройств - Google Patents

Терапевтические агенты для применения в профилактике и/или лечении гиперкинетических двигательных расстройств Download PDF

Info

Publication number
RU2685502C2
RU2685502C2 RU2016101152A RU2016101152A RU2685502C2 RU 2685502 C2 RU2685502 C2 RU 2685502C2 RU 2016101152 A RU2016101152 A RU 2016101152A RU 2016101152 A RU2016101152 A RU 2016101152A RU 2685502 C2 RU2685502 C2 RU 2685502C2
Authority
RU
Russia
Prior art keywords
compound
formula
disease
use according
syndrome
Prior art date
Application number
RU2016101152A
Other languages
English (en)
Russian (ru)
Other versions
RU2016101152A (ru
Inventor
БАТАЛЬА Нурия ГАВАЛЬДА
БОРОНАТ Рауль ИНСА
БОЛАНЬО Нурия РЕЙГ
Original Assignee
Сом Инновейшен Биотех, С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2685502(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сом Инновейшен Биотех, С.Л. filed Critical Сом Инновейшен Биотех, С.Л.
Publication of RU2016101152A publication Critical patent/RU2016101152A/ru
Application granted granted Critical
Publication of RU2685502C2 publication Critical patent/RU2685502C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2016101152A 2013-06-19 2014-06-18 Терапевтические агенты для применения в профилактике и/или лечении гиперкинетических двигательных расстройств RU2685502C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382230.4 2013-06-19
EP13382230 2013-06-19
PCT/EP2014/062786 WO2014202646A1 (en) 2013-06-19 2014-06-18 Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders

Publications (2)

Publication Number Publication Date
RU2016101152A RU2016101152A (ru) 2017-07-24
RU2685502C2 true RU2685502C2 (ru) 2019-04-19

Family

ID=48672545

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016101152A RU2685502C2 (ru) 2013-06-19 2014-06-18 Терапевтические агенты для применения в профилактике и/или лечении гиперкинетических двигательных расстройств

Country Status (19)

Country Link
US (2) US9789072B2 (enExample)
EP (1) EP3010543B1 (enExample)
JP (1) JP6476174B2 (enExample)
KR (1) KR102254542B1 (enExample)
CN (1) CN105658238B (enExample)
AU (1) AU2014283319B2 (enExample)
BR (1) BR112015031835B1 (enExample)
CA (1) CA2915811C (enExample)
CL (1) CL2015003679A1 (enExample)
DK (1) DK3010543T3 (enExample)
ES (1) ES3053333T3 (enExample)
IL (1) IL243192B (enExample)
MX (1) MX366353B (enExample)
PL (1) PL3010543T3 (enExample)
PT (1) PT3010543T (enExample)
RU (1) RU2685502C2 (enExample)
SG (1) SG11201510451RA (enExample)
WO (1) WO2014202646A1 (enExample)
ZA (1) ZA201600312B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41557A (fr) * 2015-02-18 2017-12-26 Auspex Pharmaceuticals Inc Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2
CA3076000A1 (en) * 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100203168A1 (en) * 2009-02-06 2010-08-12 Mark John Zamoyski Bone microenvironment modulated seizure treatments
RU2010115574A (ru) * 2007-09-20 2011-10-27 СиДжиАй Фамэсьютикэлс, Инк. (US) Замещенные амиды, фармацевтическая композиция на их основе, способ лечения заболевания, чувствительного к btk, способ повышения чувствительности раковых клеток к химиотерапии, способ уменьшения ошибок при приеме лекарства и улучшения соблюдения схемы лечения, способ ингибирования гидролиза атф, способ определения присутствия btk в образце и способ ингибирования активности в-клеток

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790165A (fr) * 1971-12-14 1973-02-15 Parke Davis & Co Nouveaux aminoalcanols et procede pour les preparer
ES2569483T3 (es) 2007-06-21 2016-05-11 Amgen Inc. Métodos para sintetizar cinacalcet y sales del mismo
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
RS53227B (sr) * 2011-03-01 2014-08-29 Pharnext Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2010115574A (ru) * 2007-09-20 2011-10-27 СиДжиАй Фамэсьютикэлс, Инк. (US) Замещенные амиды, фармацевтическая композиция на их основе, способ лечения заболевания, чувствительного к btk, способ повышения чувствительности раковых клеток к химиотерапии, способ уменьшения ошибок при приеме лекарства и улучшения соблюдения схемы лечения, способ ингибирования гидролиза атф, способ определения присутствия btk в образце и способ ингибирования активности в-клеток
US20100203168A1 (en) * 2009-02-06 2010-08-12 Mark John Zamoyski Bone microenvironment modulated seizure treatments

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Selectivity of Bevantolol Hydrochloride, aβ1-Adrenoceptor Antagonist, in Asthmatic Patients. Claes-Göran Löfdahl M.D. et al. First published: July-August 1984. https://doi.org/10.1002/j.1875-9114.1984.tb03359.x. Режим доступа: https://onlinelibrary.wiley.com/doi/abs/10.1002/j.1875-9114.1984.tb03359.x. Дата обращения 11.04.2018. Обследование пациентов с гиперкинетическими расстройствами. Эллисон Брэшир. Практическая неврология, 2008. Электронный ресурс. Режим доступа: https://bib.social/nevrologiya_1068/obsledovanie-patsientov-giperkineticheskimi-133014.html. Дата обращения: 11.04.2018, пар. 1-2, разд. "Хорея", "Тики", "Поздняя дискинезия", "Гемибаллизм". *
Selectivity of Bevantolol Hydrochloride, aβ1-Adrenoceptor Antagonist, in Asthmatic Patients. Claes-Göran Löfdahl M.D. et al. First published: July-August 1984. https://doi.org/10.1002/j.1875-9114.1984.tb03359.x. Режим доступа: https://onlinelibrary.wiley.com/doi/abs/10.1002/j.1875-9114.1984.tb03359.x. *
Дата обращения 11.04.2018. Обследование пациентов с гиперкинетическими расстройствами. Эллисон Брэшир. Практическая неврология, 2008. Электронный ресурс. Режим доступа: https://bib.social/nevrologiya_1068/obsledovanie-patsientov-giperkineticheskimi-133014.html. Дата обращения: 11.04.2018, пар. 1-2, разд. "Хорея", "Тики", "Поздняя дискинезия", "Гемибаллизм". *
Электронный ресурс. режим доступа: http://www.remedium.ru/doctor/detail.php?ID=16892. Дата публикации 16.07.2007. Дата обращения 11.04.2018. The role of different types of adrenergic receptors in pentylenetetrazol-induced seizures and the effect of di-n-propylacetate in the rat. Lazarova M, Bendotti C, Samanin R., Psychopharmacology (Berl). 1983;81(2):177-82. Найдено в ивной базе данных PubMed. Режим доступа: https://www.ncbi.nlm.nih.gov/pubmed/6314419. Дата обращения: 11.04.2018. *
Электронный ресурс. режим доступа: http://www.remedium.ru/doctor/detail.php?ID=16892. Дата публикации 16.07.2007. Дата обращения 11.04.2018. The role of different types of adrenergic receptors in pentylenetetrazol-induced seizures and the effect of di-n-propylacetate in the rat. Lazarova M, Bendotti C, Samanin R., Psychopharmacology (Berl). 1983;81(2):177-82. Найдено в реферативной базе данных PubMed. Режим доступа: https://www.ncbi.nlm.nih.gov/pubmed/6314419. Дата обращения: 11.04.2018. *

Also Published As

Publication number Publication date
MX366353B (es) 2019-07-05
EP3010543A1 (en) 2016-04-27
NZ715951A (en) 2021-03-26
PT3010543T (pt) 2025-11-28
US9789072B2 (en) 2017-10-17
PL3010543T3 (pl) 2026-01-19
CL2015003679A1 (es) 2016-09-02
CA2915811C (en) 2021-08-31
SG11201510451RA (en) 2016-01-28
EP3010543B1 (en) 2025-11-05
US20180042869A1 (en) 2018-02-15
CN105658238B (zh) 2019-07-12
JP6476174B2 (ja) 2019-02-27
BR112015031835B1 (pt) 2022-12-13
KR102254542B1 (ko) 2021-05-24
RU2016101152A (ru) 2017-07-24
BR112015031835A2 (pt) 2017-07-25
AU2014283319B2 (en) 2019-07-25
JP2016522235A (ja) 2016-07-28
MX2015018040A (es) 2016-08-03
IL243192A0 (en) 2016-02-29
WO2014202646A1 (en) 2014-12-24
IL243192B (en) 2019-12-31
KR20160055121A (ko) 2016-05-17
AU2014283319A1 (en) 2016-02-11
BR112015031835A8 (pt) 2019-12-31
CA2915811A1 (en) 2014-12-24
ZA201600312B (en) 2022-12-21
US20160158167A1 (en) 2016-06-09
HK1223014A1 (en) 2017-07-21
DK3010543T3 (da) 2025-12-01
CN105658238A (zh) 2016-06-08
ES3053333T3 (en) 2026-01-21

Similar Documents

Publication Publication Date Title
US6391875B2 (en) Pharmaceutically active morpholinol
TWI494293B (zh) 用於治療認知障礙之α-胺基醯胺衍生物
US20250074873A1 (en) Compounds
KR20170008320A (ko) 니코틴아미드 리보시드 유사체 및 그의 제약 조성물 및 용도
EP2296658A2 (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
JP7429942B2 (ja) テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミン（ａｎａｖｅｘ２－７３）のエナンチオマーならびにシグマ１レセプターにより調節されるアルツハイマー型および他の傷害の処置におけるその使用
KR100570374B1 (ko) 5-ｈｔ3 및 신경세포의 니코틴작용성 수용체 길항물질로서의 1-아미노-알킬시클로헥산 화합물을 이용한 치료방법 및 이 화합물을 함유하는 약학적 조성물
JP2014526551A (ja) 相応の作用を伴う調節活性を有している（ｒｓ）−２−（２−オキソ−４−フェニルピロリジン−１−イル）アセトアミド化合物、医薬物質（変種）およびその適用、それらの組成物（変形）
DE69933885T2 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen
AU2014283319B2 (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
WO1999023075A1 (en) Ortho-hydroxypyridinone derivatives as iron chelating and antioxidant agents
US7098206B2 (en) Pharmaceutically active morpholinol
US20030083330A1 (en) Pharmaceutically active morpholinol
WO2012154710A1 (en) Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptor agonists in combination with nicotine
HK1223014B (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
NZ715951B2 (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
CA3102826A1 (en) Disease modifying methods for treating neurodegenerative diseases using nootropic agents
US20140275060A1 (en) Compounds for the treatment of neurologic disorders
CN120225201A (zh) 治疗炎症性病状的方法
JP2017509617A (ja) 抗異痛活性および抗痛覚過敏活性を有する新規化合物
HK1107521A (en) Pharmaceutically active morpholinol